- Home
- EDTK vs EVAX Comparison
EDTK vs EVAX Comparison
Compare EDTK & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- EVAX
- Stock Information
- Founded
- EDTK 2013
- EVAX 2008
- Country
- EDTK China
- EVAX Denmark
- Employees
- EDTK N/A
- EVAX N/A
- Industry
- EDTK Other Consumer Services
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDTK Real Estate
- EVAX Health Care
- Exchange
- EDTK Nasdaq
- EVAX Nasdaq
- Market Cap
- EDTK 14.3M
- EVAX 15.1M
- IPO Year
- EDTK 2020
- EVAX 2021
- Fundamental
- Price
- EDTK $0.99
- EVAX $2.77
- Analyst Decision
- EDTK
- EVAX Strong Buy
- Analyst Count
- EDTK 0
- EVAX 2
- Target Price
- EDTK N/A
- EVAX $10.00
- AVG Volume (30 Days)
- EDTK 6.7K
- EVAX 107.1K
- Earning Date
- EDTK 08-18-2025
- EVAX 08-14-2025
- Dividend Yield
- EDTK N/A
- EVAX N/A
- EPS Growth
- EDTK N/A
- EVAX N/A
- EPS
- EDTK N/A
- EVAX N/A
- Revenue
- EDTK $893,690.00
- EVAX $3,293,000.00
- Revenue This Year
- EDTK N/A
- EVAX N/A
- Revenue Next Year
- EDTK N/A
- EVAX N/A
- P/E Ratio
- EDTK N/A
- EVAX N/A
- Revenue Growth
- EDTK N/A
- EVAX 2555.64
- 52 Week Low
- EDTK $0.80
- EVAX $1.20
- 52 Week High
- EDTK $1.21
- EVAX $17.75
- Technical
- Relative Strength Index (RSI)
- EDTK 56.65
- EVAX 53.83
- Support Level
- EDTK $0.86
- EVAX $2.61
- Resistance Level
- EDTK $1.05
- EVAX $2.99
- Average True Range (ATR)
- EDTK 0.06
- EVAX 0.21
- MACD
- EDTK 0.00
- EVAX -0.00
- Stochastic Oscillator
- EDTK 47.14
- EVAX 50.00
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.